RxDoctor Payments Data

Min Yan, MD

Internal Medicine · Oakland, CANPI 1447499710

Payments from drug & device makers

$50,474in general payments, 2019–2025

Across 836 payments — averaging $60.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Agios Pharmaceuticals, Inc.$8K
  • Eisai Inc.$4K
  • Pfizer$4K
  • GSK$2K
  • ADC Therapeutics America, Inc.$2K
  • plus $13K from 54 others
$1,930in research payments, 2019–2025

Across 4 payments — averaging $482.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2K

What the payments were for

  • Consulting fees$29,96559%
  • Speaking & faculty fees$1,4403%
  • Travel & lodging$6011%
  • Food & beverage$17,93136%
  • Education$5371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)78$16,524
Agios Pharmaceuticals, Inc.16$7,551
Eisai Inc.11$4,269
Pfizer87$4,203
GSK25$2,136
ADC Therapeutics America, Inc.2$2,115
Johnson & Johnson(2 entities)61$1,188
E.r. Squibb & Sons, L.L.C.79$1,178
Merck43$1,072
Takeda Pharmaceuticals U.S.A., Inc.41$686
Novartis30$680
Astellas Pharma US Inc30$623
Seagen Inc.34$583
Bristol Myers Squibb23$527
Lilly USA, LLC18$494
Gilead(2 entities)20$408
Sanofi12$325
Genentech USA, Inc.12$325
Array Biopharma Inc11$298
Bayer16$263
Pharmacyclics LLC, An Abbvie Company12$260
Amgen10$255
Daiichi Sankyo Inc.12$240
Exelixis Inc.6$220
AbbVie10$218
Myriad Genetic Laboratories, Inc.2$186
Incyte Corporation7$151
Acrotech Biopharma Inc.9$151
Kyowa Kirin, Inc.6$137
Sobi, Inc5$133
Octapharma USA, Inc.3$133
Vertos Medical, Inc.1$132
Rigel Pharmaceuticals, Inc.7$128
Tersera Therapeutics LLC5$127
Ipsen Biopharmaceuticals, Inc4$124
US Oncology Corporate, Inc.1$122
Boehringer Ingelheim5$121
Regeneron Healthcare Solutions, Inc.4$118
Integra Lifesciences Corporation2$113
Coherus Oncology, Inc.4$112
Karyopharm Therapeutics Inc.2$109
Taiho Oncology, Inc.5$104
Pharmacosmos Therapeutics Inc.4$103
Dendreon Pharmaceuticals LLC1$96
EMD Serono, Inc.5$95
Genmab U.S., Inc.3$91
Tesaro, Inc.3$82
Deciphera Pharmaceuticals Inc.3$79
Jazz Pharmaceuticals Inc.2$74
Springworks Therapeutics, Inc.3$70
KCI USA, Inc.1$62
Geron Corporation2$59
Intuitive Surgical2$58
Clovis Oncology, Inc.4$57
Puma Biotechnology, Inc.2$53
Iovance Biotherapeutics, Inc.2$49
Morphosys, US Inc.2$48
Beone Medicines USA, Inc.2$48
Pharmaessentia USA Corporation2$46
Mirati Therapeutics, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,474 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$7,323,786
Medicare patients
966
Services billed
281,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate134$2,102,021
AlecensaAlectinib Hcl24$447,552
ImbruvicaIbrutinib24$382,484
CabometyxCabozantinib S-Malate11$273,561
NubeqaDarolutamide20$258,138
CalquenceAcalabrutinib Maleate23$242,186
SprycelDasatinib12$140,961
Abiraterone Acetate27$96,979
XareltoRivaroxaban97$85,839
EliquisApixaban134$80,739
VenclextaVenetoclax22$74,039
Imatinib Mesylate30$43,971
Deferasirox13$7,792
Exemestane21$4,169
Letrozole156$2,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$16,524$2,344,207157 claims
Genentech USA, Inc.Alecensa$325$447,55224 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$260$382,48424 claims
Exelixis Inc.Cabometyx$220$273,56111 claims
BayerNubeqa$263$258,13820 claims
E.r. Squibb & Sons, L.L.C.Sprycel$1,178$140,96112 claims
Johnson & JohnsonXarelto$1,188$85,83997 claims
PfizerEliquis$4,203$80,739134 claims
AbbVieVenclexta$218$74,03922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →